Sensei Biotherapeutics Advances PIKTOR Oncology Program Following Faeth Acquisition and $200 Million Financing
Sensei Biotherapeutics reported its financial results for the first quarter ended March 31, 2026, while also outlining major strategic and clinical developments that the company believes will redefine its future direction in oncology drug development. The quarter marked a pivotal period for the company, highlighted by the acquisition of Faeth Therapeutics and the completion of a concurrent $200 million private financing backed by a syndicate of prominent life sciences investors.
The transaction significantly strengthened Sensei’s financial position and transformed its pipeline strategy by bringing in PIKTOR, a novel investigational therapy targeting the PI3K/AKT/mTOR signaling pathway. Company executives emphasized that the acquisition provides both scientific momentum and financial resources to accelerate development programs focused on difficult-to-treat solid tumors.
Christopher Gerry, President and General Counsel of Sensei Biotherapeutics, described the first quarter as a transformative phase for the organization. According to Gerry, the acquisition of Faeth Therapeutics and the substantial capital raise collectively position the company to execute on multiple upcoming clinical milestones. He noted that the financing reflects strong confidence from investors in both the company’s strategy and the therapeutic potential of PIKTOR.
The newly acquired PIKTOR program has now become Sensei’s lead oncology asset. The therapy is an all-oral investigational combination regimen consisting of serabelisib and sapanisertib. Together, the two agents are designed to inhibit multiple signaling nodes within the PI3K/AKT/mTOR pathway, a critical pathway involved in tumor growth, metabolism, survival, and resistance to therapy in many cancers.
Unlike single-target therapies, PIKTOR is designed to simultaneously inhibit PI3K-alpha as well as both mTORC1 and mTORC2 complexes. This multi-node approach is intended to improve pathway suppression while potentially overcoming resistance mechanisms that have limited the long-term effectiveness of earlier targeted therapies.
Anand Parikh, Chief Operating Officer of Sensei Biotherapeutics, stated that emerging industry data continues to validate the therapeutic relevance of multi-node inhibition within the PI3K/AKT/mTOR pathway. He explained that the company believes PIKTOR stands apart from other approaches because it combines oral administration with comprehensive pathway targeting, offering potential applicability across a broad range of solid tumors.
Parikh added that Sensei is rapidly advancing the program through clinical development. The company recently initiated a Phase 1b/2 clinical study evaluating PIKTOR in patients with HR-positive, HER2-negative advanced breast cancer, while a separate Phase 2 study in advanced endometrial cancer continues to progress toward a planned data readout later this year.
The Phase 1b/2 breast cancer trial, known as Study FTH-PIK-101, reached an important milestone in April 2026 when the first patient was dosed. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PIKTOR in patients with advanced HR+/HER2- breast cancer, one of the most common subtypes of breast cancer worldwide.
Investigators are expected to assess how effectively the therapy can suppress tumor progression while maintaining manageable safety and tolerability profiles. Interim clinical data from the study is anticipated in 2027, and the trial is expected to provide important insight into the potential role of PIKTOR within the evolving breast cancer treatment landscape.
At the same time, Sensei continues to advance Study FTH-PIK-201, a Phase 2 trial evaluating PIKTOR in advanced endometrial cancer. The study remains on track to deliver topline clinical data during the second half of 2026. Endometrial cancer represents an area of growing interest for targeted therapies due to the frequent involvement of PI3K pathway alterations in disease progression.
The company believes that positive data from the endometrial cancer program could further validate the broader therapeutic concept behind PIKTOR and potentially support expansion into additional tumor types where the PI3K/AKT/mTOR pathway plays a central role.
Financially, the quarter reflected the substantial impact of the Faeth acquisition and the associated financing activities. Sensei reported cash, cash equivalents, and marketable securities totaling $202.8 million as of March 31, 2026, a dramatic increase from $21.2 million reported at the end of 2025. The strengthened balance sheet is expected to provide the company with the operational runway needed to support ongoing and future clinical development initiatives.
Research and development expenses increased significantly during the quarter, rising to $18.0 million compared with $3.7 million during the same period in 2025. The increase was largely driven by the inclusion of Faeth Therapeutics’ research operations following the acquisition, along with one-time transaction-related expenses. The company also noted that these higher costs were partially offset by reduced spending associated with the SNS-101 clinical trial program.
General and administrative expenses also rose sharply during the quarter. Sensei reported G&A expenses of $19.7 million for the first quarter of 2026, compared with $3.5 million during the corresponding quarter of the previous year. Management attributed most of the increase to one-time acquisition-related expenses connected to the Faeth transaction.
A major contributor to the company’s quarterly loss was acquired in-process research and development expenses, commonly referred to as acquired IPR&D. Sensei recorded $133.0 million in acquired IPR&D charges during the quarter. The company explained that the charge reflects the fair value of research and development assets obtained through the acquisition that currently have no alternative future use beyond continued clinical development.
As a result of these acquisition-related costs and increased operating expenses, Sensei reported a net loss of $170.2 million for the first quarter of 2026. This compares with a net loss of $6.9 million recorded during the same quarter in 2025. On a per-share basis, the company reported a loss of $131.45 per basic and diluted share, compared with a loss of $5.45 per share during the prior-year period.
The weighted-average number of common shares outstanding was 1,295,052 for the quarter ended March 31, 2026, slightly higher than the 1,259,531 shares reported during the corresponding quarter in 2025.
The acquisition of Faeth Therapeutics signals a broader strategic evolution for Sensei Biotherapeutics as the company transitions toward a stronger focus on targeted oncology therapeutics. By integrating Faeth’s pipeline and scientific capabilities, Sensei aims to position itself within the increasingly competitive field of precision cancer medicine.
The company’s emphasis on the PI3K/AKT/mTOR pathway reflects continued industry interest in targeting signaling pathways that drive tumor growth and therapeutic resistance. While previous generations of pathway inhibitors have shown limitations due to toxicity or incomplete pathway suppression, newer multi-node approaches such as PIKTOR are being developed with the goal of achieving more durable anti-cancer responses.
Looking ahead, Sensei Biotherapeutics plans to focus on advancing its ongoing clinical trials, generating new efficacy and safety data, and leveraging its enhanced financial resources to support future development opportunities. With multiple clinical catalysts expected over the next 18 months, including upcoming endometrial cancer data and breast cancer trial updates, the company is entering a potentially defining phase in its development trajectory.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. Following the acquisition of Faeth Therapeutics, Sensei’s lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. Sensei is also completing a Phase 1/2 trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Sensei intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
